| Literature DB >> 30603027 |
Marek Grabka1, Magdalena Kocierz-Woźnowska2, Maciej Wybraniec1, Maciej Turski2, Marcin Wita1, Krystian Wita1, Katarzyna Mizia-Stec1.
Abstract
INTRODUCTION: The study aimed to evaluate the prevalence and predictors of left ventricular (LV) reverse remodeling and its impact on long-term prognosis in patients with anterior ST-segment elevation myocardial infarction (STEMI). AIM: To assess the percentage of reverse remodeling and its prognostic factors in anterior STEMI patients.Entities:
Keywords: 3D transthoracic echocardiography; acute myocardial infarction/ST-segment elevation myocardial infarction; anterior global longitudinal strain; cardiac magnetic resonance imaging; global longitudinal strain; reverse remodeling
Year: 2018 PMID: 30603027 PMCID: PMC6309837 DOI: 10.5114/aic.2018.79867
Source DB: PubMed Journal: Postepy Kardiol Interwencyjnej ISSN: 1734-9338 Impact factor: 1.426
Comparison of baseline demographic and clinical characteristics in study and control group
| Variable | LV reverse remodeling (+) ( | LV reverse remodeling (–) ( | |
|---|---|---|---|
| Male sex | 11 (78.57) | 17 (70.83) | 0.46 |
| Age [years] | 55.64 ±7.73 | 61.67 ±10.93 | 0.08 |
| Weight [kg] | 79.07 ±10.01 | 76.54 ±11.69 | 0.50 |
| Hospitalization time [days] | 6.21 ±0.98 | 6.79 ±1.10 | 0.24 |
| Time from onset of symptoms to reperfusion therapy [min] | 297.50 ±171.85 | 284.17 ±201.64 | 0.50 |
| Arterial hypertension | 13 (92.86) | 19 (79.17) | 0.26 |
| Dyslipidemia | 8 (57.14) | 20 (83.33) | 0.08 |
| Diabetes mellitus | 0 (0) | 4 (16.67) | 0.14 |
| Cigarette smoking | 9 (64.29) | 13 (54.17) | 0.40 |
| AKI in anamnesis | 0 (0) | 1 (4.17) | 0.63 |
| Stroke/TIA in anamnesis | 0 (0) | 2 (8.33) | 0.39 |
AKI – acute kidney injury, TIA – transient ischaemic attack, SD – standard deviation.
Mann-Whitney U test
Student’s t test
Fisher’s exact test.
Comparison of laboratory, electrocardiographic and imaging variables in study and control group
| Variable | LV reverse remodeling (+) ( | LV reverse remodeling (–) ( | |
|---|---|---|---|
| Multi-vessel CAD | 7 (50) | 12 (50) | 1.00 |
| Proximal LAD occlusion | 9 (64.29) | 13 (54.17) | 0.40 |
| GP IIb/IIIa inhibitor use | 10 (71.43) | 18 (75) | 0.55 |
| Serum creatinine concentration [mg/dl] | 0.88 ±0.28 | 0.83 ±0.18 | 0.71 |
| Maximal hs-TnT concentration [ng/ml] | 5.70 ±5.24 | 14.89 ±10.41 | < 0.01 |
| Maximal CK-MB concentration [U/l] | 116.00 ±135.01 | 252.55 ±238.27 | 0.08 |
| Sum of ST-segment elevations before PCI [mm] | 9.46 ±5.51 | 16.08 ±8.62 | 0.02 |
| Max. ST-segment elevation before PCI [mm] | 3.54 ±1.93 | 4.33 ±1.95 | 0.23 |
| Sum of ST-segment elevations after PCI [mm] | 3.75 ±2.56 | 8.52 ±6.52 | < 0.01 |
| Max. ST-segment elevation after PCI [mm] | 1.46 ±0.93 | 2.54 ±1.44 | 0.01 |
| Mitral valve insufficiency | 2 (14.29) | 8 (40) | 0.11 |
| Vena contracta [mm] | 0.21 ±0.58 | 1.14 ±1.75 | 0.14 |
| LVEDV – 3D-TTE [ml] | 112.99 ±36.10 | 100.79 ±23.41 | 0.21 |
| LVESV – 3D-TTE [ml] | 60.42 ±24.88 | 52.38 ±14.16 | 0.78 |
| LVESV – 3D-TTE at 3 months [ml] | 43.52 ±14.27 | 69.48 ±29.06 | < 0.01 |
| SV – 3D-TTE [ml] | 52.57 ±18.56 | 48.39 ±14.69 | 0.45 |
| LVEF – 3D-TTE [%] | 46.66 ±9.34 | 47.91 ±9.05 | 0.69 |
| Wall motion score index (WMSI) | 1.23 ±0.18 | 1.39 ±0.18 | 0.02 |
| Global longitudinal strain (GLS) [%] | –14.06 ±4.48 | –11.65 ±4.67 | 0.13 |
| Anterior global longitudinal strain (AGLS) [%] | –12.61 ± 6.33 | –7.89 ± 5.90 | 0.03b |
| LVEDV – CMR at 3 months [ml] | 101.97 ±24.74 | 121.41 ±33.21 | 0.11 |
| LVESV – CMR at 3 months [ml] | 43.52 ±14.27 | 69.48 ±29.06 | < 0.01 |
| SV – CMR at 3 months [ml] | 58.75 ±16.41 | 51.93 ±16.90 | 0.19 |
| LVEF – CMR at 3 months [%] | 57.42 ±7.86 | 44.30 ±12.78 | < 0.01 |
| LVM [g] | 144.57 ±42.36 | 145.90 ±34.89 | 0.92 |
| LV infarction mass [g] | 32.89 ±35.97 | 41.34 ±23.98 | 0.21 |
| Large myocardial infarct > 20% of LVM | 6 (42.86) | 17 (70.83) | 0.09 |
CAD – coronary artery disease, CMR – cardiac magnetic resonance, GP – glycoprotein, LAD – left anterior descending artery, LVEDV – left ventricular end-diastolic volume, LVEF – left ventricular ejection fraction, LVESV – left ventricular end-systolic volume, SV – stroke volume, 3D-TTE – 3-dimensional transthoracic echocardiography, LVM – left ventricular mass, PCI – percutaneous coronary interventions, CK-MB – creatine kinase MB fraction, hs-TnT – high-sensitivity troponin T, SD – standard deviation
Mann-Whitney U test
Student’s t test
Fisher’s exact test.
Analysis of correlation between different clinical variables and the change of 3-month left ventricular end-systolic velocity (∆ LVESV – 3D-TTE) in relation to baseline value as assessed in 3D-TTE
| ∆LVESV vs. | Spearman | |
|---|---|---|
| Maximal hs-TnT concentration | 0.53 | < 0.05 |
| Sum of ST-segment elevations before PCI | 0.40 | 0.01 |
| Sum of ST-segment elevations after PCI | 0.46 | < 0.05 |
| Max. ST-segment elevation after PCI | 0.40 | 0.01 |
| MVI vena contracta | 0.35 | 0.03 |
| Global longitudinal strain | 0.37 | 0.02 |
| Anterior global longitudinal strain | 0.40 | 0.01 |
| LVEF – CMR at 3 months | –0.63 | < 0.05 |
∆LVESV – change of ESV between baseline and follow-up at 3 months, LVEF – left ventricular ejection fraction, hs-TnT – high-sensitivity troponin T, PCI – percutaneous coronary intervention, MVI – mitral valve insufficiency, Max. – maximal, CMR – cardiac magnetic resonance imaging.
Univariate analysis of different predictors of left ventricular reverse remodeling
| Variable | OR | 95% CI | |
|---|---|---|---|
| Age [per 1 year] | 0.94 | 0.87–1.01 | 0.09 |
| Hospitalization time [per 1 day] | 0.59 | 0.29–1.1 | 0.13 |
| Hyperlipidemia | 0.27 | 0.056–1.27 | 0.09 |
| Maximal hs-TnT concentration [per 1 ng/ml] | 0.86 | 0.75–0.98 | 0.02 |
| Maximal CK-MB concentration [per 1 U/l] | 0.99 | 0.99–1.0 | 0.098 |
| Sum of ST-segment elevations before PCI [per 1 mm] | 0.87 | 0.77–0.99 | 0.03 |
| Sum of ST-segment elevations after PCI [per 1 mm] | 0.69 | 0.51–0.93 | 0.02 |
| Max. ST-segment elevation after PCI [per 1 mm] | 0.40 | 0.17–0.93 | 0.03 |
| Wall motion score index [per 1 unit] | 0.01 | 0.00–0.63 | 0.03 |
| Anterior global longitudinal strain [per 1 unit] | 0.88 | 0.78–1.00 | 0.045 |
| Global longitudinal strain [per 1 unit] | 0.89 | 0.76–1.04 | 0.15 |
OR – odds ratio, 95% CI – 95% confidence interval, CK-MB – creatine kinase MB fraction, hs-TnT – high-sensitivity troponin T.
Figure 1Kaplan-Meier curve of major adverse cardiovascular events depending on the presence of reverse left ventricular remodeling in 4-year observation
MACE – major adverse cardiovascular events, MI – myocardial infarction, 3D-TTE – 3-dimensional transthoracic echocardiography, arrow – point of 3D-TTE assessment of LV reverse remodeling at 3-month follow-up.
Univariate Cox analysis of different predictors of composite endpoint (death, myocardial infarction, urgent coronary revascularization, heart failure hospitalization)
| Variable | HR | 95% CI | |
|---|---|---|---|
| Age [per 1 year] | 1.10 | 0.99–1.22 | 0.07 |
| Arterial hypertension | 0.69 | 0.08–6.18 | 0.74 |
| Diabetes mellitus | 1.92 | 0.21–17.16 | 0.56 |
| Cigarette smoking | 1.12 | 0.19–6.68 | 0.90 |
| Time of onset of symptoms to reperfusion therapy [per 1 min] | 0.99 | 0.98–1.00 | 0.09 |
| Multi-vessel CAD | 4.47 | 0.50–40.00 | 0.18 |
| Proximal LAD occlusion | 1.14 | 0.19–6.82 | 0.89 |
| GP IIb/IIIa antagonist use | 1.51 | 0.17–13.49 | 0.71 |
| Serum creatinine concentration [per 1 mg/dl] | 0.00 | 0.00–2.62 | 0.09 |
| Maximal hs-TnT concentration [per 1 ng/ml] | 1.06 | 0.98–1.15 | 0.15 |
| Maximal CK-MB concentration [per 1 U/l] | 1.00 | 1.00–1.01 | 0.30 |
| NYHA class at admission [per 1 class] | 37.73 | 2.38–597.29 | 0.01 |
| NYHA class at discharge [per 1 class] | 1.75 | 0.56–5.47 | 0.33 |
| CCS class at discharge [per 1 class] | 1.52 | 0.52–4.43 | 0.44 |
| Sum of ST-segment elevations before PCI [per 1 mm] | 1.12 | 1.01–1.23 | 0.03 |
| Sum of ST-segment elevations after PCI [per 1 mm] | 1.12 | 1.02–1.22 | 0.02 |
| Max. ST-segment elevation before PCI [per 1 mm] | 1.74 | 1.03–2.92 | 0.04 |
| Max. ST-segment elevation after PCI [per 1 mm] | 1.71 | 1.04–2.81 | 0.04 |
| Presence of MVI | 5.73 | 0.84–39.16 | 0.08 |
| MVI – vena contracta [per 1 mm] | 1.56 | 1.07–2.27 | 0.02 |
| LVEDV – 3D-TTE [per 1 ml] | 0.99 | 0.96–1.03 | 0.65 |
| LVESV – 3D-TTE [per 1 ml] | 1.01 | 0.97–1.05 | 0.59 |
| SV – 3D-TTE [per 1 ml] | 0.95 | 0.88–1.02 | 0.14 |
| LVEF – 3D-TTE [per 1%] | 0.87 | 0.78–0.98 | 0.02 |
| Wall motion score index [per 1 unit] | 17064.2 | 16.00–18198120 | 0.01 |
| Global longitudinal strain [per 1 unit] | 1.32 | 1.00–1.73 | 0.05 |
| Anterior global longitudinal strain [per 1 unit] | 1.29 | 1.02–1.63 | 0.04 |
| LV reverse remodeling | 0.004 | < 0.001– 68717.43 | 0.51 |
HR – hazard ratio, CI – confidence interval, CAD – coronary artery disease, GP – glycoprotein, LAD – left anterior descending artery, LVEDV – left ventricular end-diastolic volume, LVEF – left ventricular ejection fraction, LVESV – left ventricular end-systolic volume, MVI – mitral valve insufficiency, SV – stroke volume, 3D-TTE – 3-dimensional transthoracic echocardiography, PCI – percutaneous coronary interventions, CK-MB – creatine kinase MB fraction, hs-TnT – high-sensitivity troponin T, SD – standard deviation.